SHP2 Inhibition Influences Therapeutic Response to Tepotinib in Tumors with MET Alterations.
Pudelko L, Jaehrling F, Reusch C, Vitri S, Stroh C, Linde N, Sanderson MP, Musch D, Lebrun CJ, Keil M, Esdar C, Blaukat A, Rosell R, Schumacher KM, Karachaliou N.
Pudelko L, et al. Among authors: musch d.
iScience. 2020 Nov 20;23(12):101832. doi: 10.1016/j.isci.2020.101832. eCollection 2020 Dec 18.
iScience. 2020.
PMID: 33305187
Free PMC article.